Willow vs bmiMD: Oral GLP-1 vs Compounded Tirzepatide Compared
Quick verdict: Willow positions a telehealth-first oral GLP-1 program focused on structured progress tracking and follow-up, while bmiMD emphasizes compounded tirzepatide with multi-month pricing, free shipping and clinician review. Treatment with either provider is available only when a licensed clinician determines it is medically appropriate.
Explore Willow oral GLP-1 and tracking
Willow vs bmiMD: what each provider emphasizes
Willow emphasizes a structured weight management journey around an oral GLP-1, highlighting licensed telehealth clinicians, progress tracking tools and follow-up consultations to support behavior change. bmiMD emphasizes compounded tirzepatide (a GLP-1/GIP option) with multiple billing options, free subscription shipping and 24/7 clinician access. Both state that treatment is available only when a licensed clinician determines it is medically appropriate. Both note that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Key differences organized by distinctive features
1. Medication format and focus
Willow: oral GLP-1 program framed as a structured journey with digital follow-up. bmiMD: compounded tirzepatide (GLP-1/GIP). The sources explicitly present Willow as oral GLP-1 and bmiMD as compounded tirzepatide.
2. Pricing and billing structures
Willow: starting price listed as 299 with a single captured price point. bmiMD: multiple billing options with tiered monthly equivalents – $179 month-to-month; $159/mo three-month plan; $149/mo six-month plan; $139/mo 12-month plan. bmiMD notes the lowest price requires a 12-month commitment and that total prepaid charge should be confirmed.
3. Delivery, access, and follow-up
Willow highlights progress tracking tools and follow-up consultations as part of a simple digital workflow and licensed telehealth team. bmiMD highlights free subscription shipping, online refills and 24/7 clinician access, with medication prepared in a state-licensed pharmacy and independent verification claims on the captured page.
4. Regulatory and safety qualifiers
Both providers include the regulatory qualifier that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Willow also flags that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. bmiMD repeats that compounded medications are not FDA-approved and notes checking eligibility, state availability and confirmation of total prepaid charge.
Side-by-side comparison table
| Criteria | Willow | bmiMD |
|---|---|---|
| Primary offering | Oral GLP-1 with progress tracking | Compounded tirzepatide (GLP-1/GIP) |
| Starting price | Starting at 299 | From $179 monthly; $139/mo with 12-month plan |
| Billing options | Captured price 299 | 1, 3, 6, 12 month options with different monthly equivalents |
| Support and follow-up | Licensed telehealth team, follow-up consultations, tracking tools | 24/7 clinician access, online refills, delivery to door |
| Shipping | Not verified on captured page | Free subscription shipping |
| Regulatory note | Medication-specific approval status must be confirmed; compounded products not interchangeable | Compounded medications not FDA-approved; confirm eligibility and state availability |
How to choose between Willow and bmiMD
If you prioritize structured digital follow-up, behavioral scaffolding and progress tracking around an oral GLP-1, Willow is presented as best for users who want structured digital follow-up. If you prioritize lower long-term monthly equivalents, multiple billing choices and free subscription shipping for compounded tirzepatide, bmiMD is framed as best for people who confirm eligibility, medication, total cost, renewal terms and state availability before enrollment.
View bmiMD tirzepatide plans and shipping
Additional practical points from the captured evidence
Willow is described as telehealth-first with a simple digital workflow. The captured Willow page had limited readable evidence and showed an error in browser verification. bmiMD captured landing-page evidence lists specific multi-month pricing, free shipping and claims about pharmacy preparation and verification; bmiMD also notes a 100% refundable policy if not eligible, as captured on the landing page.
Check bmiMD eligibility and plans
Conclusion: Willow vs bmiMD
Willow vs bmiMD shows a clear tradeoff in the captured evidence: Willow focuses on oral GLP-1 in a structured program with tracking and follow-up; bmiMD focuses on compounded tirzepatide with tiered pricing and free shipping. Both require clinician review and note that compounded medications are not FDA-approved.
Choose Willow if you want structured digital follow-up, licensed telehealth clinicians and progress tracking tools. Choose bmiMD if you want compounded tirzepatide with multiple billing options and free subscription shipping, and you will confirm eligibility, state availability and total prepaid terms before enrolling.